

# **Birch Pollen Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/BD0A2E3BDEF8EN.html>

Date: March 2022

Pages: 36

Price: US\$ 2,000.00 (Single User License)

ID: BD0A2E3BDEF8EN

## **Abstracts**

Birch Pollen Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Birch Pollen Allergy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Birch Pollen Allergy (Immunology) pipeline landscape.

Birch pollen allergy is a reaction which occurs soon after exposure to pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching, or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies. Treatment includes drugs belonging to class of antihistamines.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Birch Pollen Allergy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Birch Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of

the therapeutics, its complete research and development history and latest news and press releases.

The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1, 1 and 1 respectively.

Birch Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy (Immunology).

The pipeline guide reviews pipeline therapeutics for Birch Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Birch Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Birch Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Birch Pollen Allergy (Immunology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Birch Pollen Allergy (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Birch Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Birch Pollen Allergy - Overview
- Birch Pollen Allergy - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Birch Pollen Allergy - Therapeutics Assessment
- Assessment by Target
- Assessment by Route of Administration
- Assessment by Molecule Type
- Birch Pollen Allergy - Companies Involved in Therapeutics Development
- Allergy Therapeutics Plc
- Desentum Oy
- HAL Allergy BV
- Regeneron Pharmaceuticals Inc
- Roxall Medizin GmbH
- S-TARget therapeutics GmbH
- Worg Pharmaceuticals Hangzhou Co Ltd
- Birch Pollen Allergy - Drug Profiles
- Allergen for Birch Pollen Allergy - Drug Profile
- Product Description
- Mechanism Of Action
- birch pollen allergen extract - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DM-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Pollinex Quattro Birch - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- REGN5713-5714-5715 - Drug Profile
- Product Description

Mechanism Of Action

History of Events

SG-300 - Drug Profile

Product Description

Mechanism Of Action

WP-1074 - Drug Profile

Product Description

Mechanism Of Action

Birch Pollen Allergy - Dormant Projects

Birch Pollen Allergy - Discontinued Products

Birch Pollen Allergy - Product Development Milestones

Featured News & Press Releases

Oct 25, 2021: Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults

Nov 01, 2019: Desentum will run a clinical trial on its allergy vaccine this winter supported by 4 M€ of new investments

Mar 18, 2019: Allergy Therapeutics' birch pollen product fails to meet primary endpoint

Aug 14, 2018: HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany

Jun 14, 2017: Desentum has two presentations in EAACI 2017

May 10, 2017: Desentum is preparing to start clinical trials with birch pollen allergy vaccine

Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study

May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy

May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasonal Allergic Rhinitis

Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria

Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen

May 12, 2013: Desentum: EARTO innovation prize to VTT

Mar 09, 2006: Stallergenes Reports Positive Study Results with Biomay's Bet v

Appendix

Methodology

Coverage

Secondary Research

[Primary Research](#)  
[Expert Panel Validation](#)  
[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Birch Pollen Allergy, 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Birch Pollen Allergy - Pipeline by Allergy Therapeutics Plc, 2022  
Birch Pollen Allergy - Pipeline by Desentum Oy, 2022  
Birch Pollen Allergy - Pipeline by HAL Allergy BV, 2022  
Birch Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, 2022  
Birch Pollen Allergy - Pipeline by Roxall Medizin GmbH, 2022  
Birch Pollen Allergy - Pipeline by S-TARget therapeutics GmbH, 2022  
Birch Pollen Allergy - Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022  
Birch Pollen Allergy - Dormant Projects, 2022  
Birch Pollen Allergy - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Birch Pollen Allergy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Birch Pollen Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/BD0A2E3BDEF8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BD0A2E3BDEF8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

